Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease

作者：Kaikai Zhao, Juan Zhang, Qun-yu Kong, Yong Zhang, Cong Li, Kaikai Huo, Na Fan, Wenjing Deng, Jie Shi, Chunya Wang, Xueyi Li, Shuanying Yang, Ping Fang · 发表于：Arthritis Research & Therapy · 年份：2025 · DOI：10.1186/s13075-025-03485-z · 被引用次数：12 · 研究领域：Inflammatory Myopathies and Dermatomyositis、Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis、Systemic Sclerosis and Related Diseases

BACKGROUND: Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, diagnosis and treatment are often delayed due to atypical early clinical features and heterogeneity. Therefore, clinical features should be identified to establish a prognosis model for early identification and intervention, thereby improving the clinical prognosis of patients. OBJECTIVES: The study aimed to investigate the clinical features, risk factors, treatment strategy, and construct a survival prognosis model for anti-MDA5 antibody + DM patients with ILD. METHODS: A total of 40 anti-MDA5 antibody + DM-ILD patients admitted to the Department of Pulmonary and Critical Care Medicine and the Department of Rheumatology and Immunology in the Second Affiliated Hospital of Xi 'an Jiaotong University from September 2018 to May 2022 were retrospectively analyzed. Prognostic factors correlated with overall survival (OS) during hospitalization were identified by multivariate Cox regression analysis, and a nomogram was established. The nomogram was internally validated using C-index and time-dependent (at 1-, 2-, and 3- months) calibration curves with 1000 iterations of bootstrap resampling. Moreover, the optimal truncation values for continuous variables and Kaplan-Meier (K-M) curves were determi...